OncoMatch/Clinical Trials/Amivantamab
Amivantamab (Rybrevant) Clinical Trials
Amivantamab (Rybrevant, JNJ-61186372) is a bispecific antibody targeting EGFR and MET, combining receptor downregulation with immune cell-directing (ADCC/ADCP) activity in a mechanism distinct from small-molecule TKIs. It received initial FDA approval in 2021 for EGFR exon 20 insertion–mutant advanced NSCLC after platinum-based chemotherapy based on the CHRYSALIS trial. In 2024, two additional FDA approvals expanded its use: amivantamab plus lazertinib (Lazcluze) for first-line EGFR-mutant (exon 19 deletion or L858R) advanced NSCLC based on MARIPOSA, and amivantamab plus carboplatin-pemetrexed for first-line EGFR exon 20 insertion NSCLC based on PAPILLON. A subcutaneous formulation was approved in December 2025 to reduce IV infusion burden. Active trials explore post-osimertinib combinations informed by the completed MARIPOSA-2 trial, and evaluation in MET-amplified or MET exon 14–skipping NSCLC. Eligibility varies by indication: EGFR exon 20 insertion or standard sensitizing EGFR mutation (del19/L858R) required depending on the trial.
Check eligibility by cancer type
Recruiting Amivantamab trials
Ranked by phase and US site count. Filter by your biomarker profile →
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Janssen Research & Development, LLC
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Janssen Research & Development, LLC
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Janssen Research & Development, LLC
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Janssen Research & Development, LLC
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development, LLC
More Amivantamab trials
4 international trials (no US sites)
How OncoMatch helps you find Amivantamab trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Amivantamab trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.